This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Exploration of the Synovial Fluid Inflammation Mediators Under Diacerhein in Knee Osteoarthritis

This study has been completed.
Information provided by:
Laboratoires NEGMA Identifier:
First received: February 26, 2007
Last updated: March 3, 2010
Last verified: October 2007
Some inflammation mediators, notably IL-1, are implied in the joint degeneration phenomena of osteoarthritis. The aim of this study is to confirm in vivo the favourable effect of diacerhein on IL-1 and also to appreciate its effect on other synovial inflammation mediators.

Condition Intervention Phase
Osteoarthritis Drug: Diacerhein Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Exploratory Study of Some Synovial Fluid Inflammation Mediatorsunder Diacerhein in Knee Osteoarthritis Patients. Phase IV Study.

Resource links provided by NLM:

Further study details as provided by Laboratoires NEGMA:

Primary Outcome Measures:
  • Synovial concentration of IL-1

Secondary Outcome Measures:
  • Synovial concentration of IL-6

Estimated Enrollment: 96
Study Start Date: March 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   45 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Painful osteoarthritis
  • Hydarthrosis (synovial effusion)

Exclusion Criteria:

  • large effusion
  • severe pathologies
  • anti-osteoarthritic treatments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00440661

Canada, Quebec
Rheumatologic Institut of Montreal
Montreal, Quebec, Canada, H2L1S6
Sponsors and Collaborators
Laboratoires NEGMA
Principal Investigator: Jean-Pierre RAYNAULD, MD Institut de Rhumatologie de Montreal
  More Information

Responsible Party: Patrick Darses, Negma-Lerads Identifier: NCT00440661     History of Changes
Other Study ID Numbers: HEC/ART06572N
Study First Received: February 26, 2007
Last Updated: March 3, 2010

Keywords provided by Laboratoires NEGMA:
Osteoarthritis, IL-1

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Pathologic Processes
Anti-Inflammatory Agents processed this record on August 21, 2017